|
On the HERA trial, where everyone got herceptin every three weeks, the incidence of heart problems was fairly low. The rate of congestive heart failure was only .5%. Since HERA was a really big trial, I am a bit surprised that your oncologist had never heard of it.
The doctor who presented the trial results at ASCO in May on all of the herceptin trials, including HERA, stated that it was really the proximity of herceptin to adriamycin, rather than herceptin itself, which seemed to cause serious heart problems in women with early breast cancer.
|